cangrelor-sodium

Description: Cangrelor sodium is a potent, reversible and selective P2Y12 inhibitor approved in June 2015 as an antiplatelet drug for intravenous application. Cangrelor is a high-affinity, reversible inhibitor of P2Y12 receptors that causes almost complete inhibition of ADP-induced platelet aggregate. It is a modified ATP analogue stable to enzymatic degradation. It does not require metabolic conversion to an active metabolite. This allows cangrelor’s immediate effect after infusion, and the therapeutic effects can be maintained with continuous infusion.

References: Judge HM, Buckland RJ, Jakubowski JA, Storey RF. Cangrelor inhibits the binding of the active metabolites of clopidogrel and prasugrel to P2Y(12) receptors in vitro. Platelets. 2015 Aug 13:1-5. Epub ahead of print PubMed PMID: 26270719.

Related CAS #: 163706-06-7 (free acid) 163706-36-3 (sodium)